Oncolytics Biotech (ONCY) Net Cash Flow (2009 - 2025)

Oncolytics Biotech (ONCY) has reported Net Cash Flow for 17 consecutive years, with -$232000.0 the latest figure, recorded in Q4 2025.

• On a quarterly basis, Net Cash Flow rose 97.09% year-over-year to -$232000.0 in Q4 2025; TTM through Dec 2025 was -$2.6 million, a 87.11% increase from a year earlier, with the FY2025 full-year figure at -$6.0 million, up 69.81% from the prior year.
• Net Cash Flow was -$232000.0 for Q4 2025 at Oncolytics Biotech, up from -$1.8 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $117.1 million in Q2 2022 and troughed at -$31.3 million in Q4 2021.
• A 5-year average of $3.0 million and a median of -$1.4 million in 2022 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow slumped 1065.31% in 2021 and surged 12129.96% in 2022, its largest moves.
• Over 5 years, Net Cash Flow stood at -$31.3 million in 2021, then climbed by 23.27% to -$24.0 million in 2022, then surged by 54.09% to -$11.0 million in 2023, then rose by 27.66% to -$8.0 million in 2024, then soared by 97.09% to -$232000.0 in 2025.
• The last three Net Cash Flow figures came in at -$232000.0 (Q4 2025), -$1.8 million (Q3 2025), and -$70727.8 (Q2 2025), per Business Quant data.